Compare Davita Inc (DVA) vs Freeport-McMoRan Inc (FCX) Price & Performance

DaVita (DVA) trades at $179.25, up 1.4% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish moving averages but neutral oscillators, trading near resistance at $179. Fundamentally, revenue growth continues with 2025 revenue reaching $13.64B, though net margins compressed to 5.47% from 7.3% in 2024. Recent partnership expansion with Humana for value-based kidney care represents significant growth opportunity.

Outlook remains positive with analyst consensus target of $235.67 implying 31% upside, though elevated debt levels and regulatory risks require monitoring. The company benefits from demographic tailwinds in kidney care services and strong institutional support, including Berkshire Hathaway's 45% stake, providing stability amid market volatility.

Freeport-McMoRan (FCX) trades at $73.69, up 2.54% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains solid fundamentals with $25.9B revenue, 11.38% net margin, and positive cash flow trends. Recent news highlights copper demand growth from AI/data centers, positioning FCX to benefit from favorable commodity trends while managing cost pressures.

FCX presents a mixed outlook with analyst consensus at Buy (61%) and $73.27 price target near current levels. Upside potential exists from copper's structural deficit and expansion projects, but risks include rising production costs, margin pressure, and ongoing legal investigation. The stock offers exposure to copper's AI-driven demand while facing execution challenges in a volatile commodity environment.